cancer cell lines related to the lung and liver subtypes. Moreover, 6f was examined on both cell cycle progression and apoptosis induction in HuH7 cancer cells. Furthermore, the in vivo antitumor activity of 6f was further assessed in female mice with solid Ehrlich carcinoma. In addition, molecular docking and molecular dynamics simulations were carried out. Collectively, 6f, 8a, and 8b could be considered
在此,对先前报道的 BIBR1591 进行修改以获得具有改进活性的
生物电子等排候选物。研究了新提供的候选物对端粒酶靶标的抑制百分比。值得注意的是,与 BIBR1532 和 BIBR1591(分别为 69.64 和 51.58%)相比, 6f实现了优异的端粒酶抑制(63.14%)。此外, 8a和8b显示出相当有前途的端粒酶抑制率,分别为58.65%和55.57%,这被记录为BIBR1591的前沿。图6f 、 8a和8b针对与肺和肝亚型相关的五种癌
细胞系进行了测试。此外,还检查了6f对 HuH7 癌细胞的细胞周期进程和细胞凋亡诱导的影响。此外,在患有实体艾氏癌的雌性小鼠中进一步评估了6f的体内抗肿瘤活性。此外,还进行了分子对接和分子动力学模拟。总的来说, 6f 、 8a和8b可以被认为是潜在的新型端粒酶
抑制剂,有待进一步研究和/或优化。